Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CPB1 | P15086 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368969 | 1.00 | EPHX1 (0.55) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL14392357 | 1.00 | EPHX1 (0.55) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL3883690 | 1.00 | EPHX1 (0.55) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL19515030 | 1.00 | EPHX1 (0.55) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL26253804 | 0.99 | EPHX1 (0.57) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL28523904 | 0.92 | CPB1 (0.58) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL15046656 | 0.92 | CPB1 (0.58) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL30060973 | 0.92 | CPB1 (0.58) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL30617864 | 0.89 | CPB1 (0.66) | EPHX1CASP3ALDH1A1GAACPB1 | |
| SCHEMBL6612597 | 0.89 | EPHX1 (0.63) | EPHX1CASP3ALDH1A1GAACPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-6984651-B2 | Piperidine amides as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA, COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-6974869-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | DELUCCA GEORGE V | 2005-11-24 | — | — | US | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-20040082790-A1 | Piperidine amides as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-04-29 | — | — | US | disclosed |
| US-6638950-B2 | Antiasthmatics and antiallergens, treating autoimmune pathologies such as rheumatoid arthritis and atherosclerosis | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-28 | — | — | US | disclosed |
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-31 | — | — | US | disclosed |
| EP-1296949-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2001098268-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | EPHX1 817/4885CASP3 4372/4885ALDH1A1 1127/4885 |
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | CCR3, CCR1, ACKR3 | EPHX1 2452/4885CASP3 2680/4885ALDH1A1 1698/4885 |
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | EPHX1 1536/4885CASP3 1742/4885ALDH1A1 1047/4885 |
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | EPHX1 1476/4885CASP3 2107/4885ALDH1A1 528/4885 |
| US-20040082790-A1 | Piperidine amides as modulators of chemokine receptor activity | CCR3, CCR1, CCL11 | EPHX1 1912/4885CASP3 1774/4885ALDH1A1 722/4885 |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | EPHX1 1512/4885CASP3 2116/4885ALDH1A1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.